Welcome to Pfanstiehl, Inc. Founded in 1919 by Carl A. Pfanstiehl, our company specializes in isolation, purification, custom synthesis and scale-up development of regulated, high purity and low endotoxin (HPLE) Injectable Formulation Ingredients, Pharmaceutical Intermediates and Active Pharmaceutical Ingredients (API’s), in gram to multi-ton commercial quantities. Pfanstiehl is known as the world’s leading supplier of high purity low endotoxin carbohydrates produced under API-level cGMP, ICH-Q7 compliant conditions. Pfanstiehl manufactures HPLE sugar-based excipients including high quality versions of Sucrose, Trehalose, Maltose, Mannose, and Galactose for injectables and upstream optimization for use in today’s risk-based regulatory environments. Pfanstiehl is also a cGMP small molecule API CDMO, specializing in carbohydrates, nucloeosides, and new chemical entities (NCE’s). Pfanstiehl manufactures generic API’s such as Streptozotocin and Cytarabine (among others), and has several new products under development. In addition, Pfanstiehl offers large volume parenterals including sodium and ammonium lactates.